)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Context Therapeutics
Context Therapeutics (CNTX) investor relations material
Context Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Portfolio focused on CTIM-76 and CT-202 after internal CT-95 development ended; trial wind-down is expected to finish promptly, with no future material program costs expected.
CTIM-76 weekly dosing showed a 22% confirmed ORR, 56% DCR and 5.6-month median PFS in heavily pretreated PROC patients; Q3W escalation advanced to 420 µg.
Q3 2026 net loss was $7.6M; cash of $34.4M is expected to fund operations to early Q4 2027, but substantial doubt about going concern remains.
Financial highlights
Q3 R&D expense was $5.7M vs. $8.7M in Q3 2025, down 34%; lower CT-202 costs drove the decrease, partly offset by higher CTIM-76, CT-95 and personnel costs.
Q3 G&A was $2.2M vs. $1.9M; net loss was $7.6M vs. $9.7M, and interest income fell 60% YoY to $0.3M.
9M R&D rose 26% YoY to $25.3M, G&A rose 19% to $7.0M, and net loss increased 34% to $30.9M; interest income fell 53% to $1.3M.
Operating cash use was $25.0M in 9M 2026 vs. $17.4M in 9M 2025; cash and equivalents declined to $34.4M from $66.0M at Dec. 31, 2025.
Outlook and guidance
Cash at Sept. 30, 2026 is expected to fund operations to early Q4 2027, but estimates depend on assumptions and cash could be used sooner than expected.
CTIM-76 Phase 1b dose expansion is expected to start in Q1 2027; initial Q3W Phase 1a efficacy data are expected in Q2 2027.
Initial CT-202 Phase 1a data are expected in 2H 2027; a U.S. IND filing is on track by year-end 2026.
Additional capital is required; potential sources include equity or debt offerings, collaborations, strategic transactions, and licensing or marketing arrangements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Context Therapeutics
- Promising T cell engager pipeline targets high unmet needs in solid tumors with strong early data.CNTX
Corporate presentation - R&D costs rose sharply as focus shifted to CTIM-76 and CT-202, with cash runway into Q4 2027.CNTXQ2 2026
- Promising T cell engager pipeline shows early efficacy and safety in solid tumors.CNTXCorporate presentation
- 29% response rate and low-grade CRS observed in late-line ovarian cancer patients.CNTXStudy result
- Lead T-cell engager shows early promise in ovarian cancer; key data updates expected soon.CNTXJefferies Global Healthcare Conference 2026
- Net loss rose to $8.7 million as R&D spending accelerated and cash runway extends into mid-2027.CNTXQ1 2026
- Key votes include director elections, auditor ratification, and a proposal to increase authorized shares.CNTXProxy filing
- Key votes include director elections, auditor ratification, and a proposed share increase.CNTXProxy filing
- Key votes include director elections, auditor ratification, and increasing authorized shares.CNTXProxy filing
Next Context Therapeutics earnings date
Q4 202619 Mar, 2027
Context Therapeutics
Next Context Therapeutics earnings date
Q4 202619 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for solid tumors. The company's primary focus is on T cell-engaging bispecific antibodies, including its lead candidate, CTIM-76. This investigational therapy targets Claudin 6 (CLDN6), a protein expressed in various solid tumors such as ovarian, endometrial, and testicular cancers, while being minimally present in healthy tissues. Another key candidate in their pipeline is CT-95, a bispecific antibody targeting mesothelin, which is also aimed at treating solid tumors. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.